You are here: Home » Companies » News
Business Standard

Piramal aims to be among top 3 in OTC business

In the past two years, Piramal has made six acquisitions in the health care business, of which three are for the OTC business

Abhineet Kumar & Aneesh Phadnis  |  Mumbai 

Piramal Enterprises aims to be among the top three players in four years in the $2.2-billion over-the-counter (OTC) pharmaceutical products business, climbing from seventh slot at present. This could be an ambitious target in a highly competitive market led by multinationals  GlaxoSmithKline and Reckitt Benckiser, and domestic household names like Dabur and Emami. But with Rs 15,000 crore in cash and investments on the books of Piramal Enterprises, competition is watching the moves of Nandini Piramal carefully. Piramal scion is directly responsible for growth of this ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
RECOMMENDED FOR YOU

Piramal aims to be among top 3 in OTC business

In the past two years, Piramal has made six acquisitions in the health care business, of which three are for the OTC business

In the past two years, Piramal has made six acquisitions in the health care business, of which three are for the OTC business Piramal Enterprises aims to be among the top three players in four years in the $2.2-billion over-the-counter (OTC) pharmaceutical products business, climbing from seventh slot at present. This could be an ambitious target in a highly competitive market led by multinationals  GlaxoSmithKline and Reckitt Benckiser, and domestic household names like Dabur and Emami. But with Rs 15,000 crore in cash and investments on the books of Piramal Enterprises, competition is watching the moves of Nandini Piramal carefully. Piramal scion is directly responsible for growth of this ... image
Business Standard
177 22

Piramal aims to be among top 3 in OTC business

In the past two years, Piramal has made six acquisitions in the health care business, of which three are for the OTC business

Piramal Enterprises aims to be among the top three players in four years in the $2.2-billion over-the-counter (OTC) pharmaceutical products business, climbing from seventh slot at present. This could be an ambitious target in a highly competitive market led by multinationals  GlaxoSmithKline and Reckitt Benckiser, and domestic household names like Dabur and Emami. But with Rs 15,000 crore in cash and investments on the books of Piramal Enterprises, competition is watching the moves of Nandini Piramal carefully. Piramal scion is directly responsible for growth of this ...

image
Business Standard
177 22